ProMACE-MOPP regimen: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of Prolix (Prednisone), Methotrexate, Doxorubicin|Adria...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[ | {{PAGENAME}} refers to a regimen consisting of [[prednisone|prolix (prednisone)]], [[methotrexate]], [[doxorubicin|adriamycin (doxorubicin)]], [[cyclophosphamide]], [[etoposide]], [[mechlorethamine|mustargen (mechlorethamine)]], [[vincristine|oncovin (vincristine)]], [[procarbazine]], [[prednisone]] used to treat [[diffuse large B-cell lymphoma]]<ref name="pmid7517442">{{cite journal| author=Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A et al.| title=MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. | journal=J Clin Oncol | year= 1994 | volume= 12 | issue= 7 | pages= 1366-74 | pmid=7517442 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7517442 }} </ref> and [[primary CNS lymphoma]].<ref name="pmid15747120">{{cite journal| author=Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H et al.| title=Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. | journal=Ann Hematol | year= 2005 | volume= 84 | issue= 7 | pages= 447-55 | pmid=15747120 | doi=10.1007/s00277-005-1005-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15747120 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|Pro|Prednisone}} | {{chemo|Pro|Prednisone}} | ||
{{chemo|M|Methotrexate}} | {{chemo|M|Methotrexate}} | ||
{{chemo|A|Adriamycin (Doxorubicin)}} | {{chemo|A|Adriamycin (Doxorubicin)}} | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
| Line 23: | Line 26: | ||
==Indications== | ==Indications== | ||
*[[Diffuse large B-cell lymphoma]]<ref name="pmid7517442">{{cite journal| author=Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A et al.| title=MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. | journal=J Clin Oncol | year= 1994 | volume= 12 | issue= 7 | pages= 1366-74 | pmid=7517442 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7517442 }} </ref> and [[primary CNS lymphoma]]<ref name="pmid15747120">{{cite journal| author=Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H et al.| title=Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. | journal=Ann Hematol | year= 2005 | volume= 84 | issue= 7 | pages= 447-55 | pmid=15747120 | doi=10.1007/s00277-005-1005-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15747120 }} </ref> | *[[Diffuse large B-cell lymphoma]]<ref name="pmid7517442">{{cite journal| author=Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A et al.| title=MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. | journal=J Clin Oncol | year= 1994 | volume= 12 | issue= 7 | pages= 1366-74 | pmid=7517442 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7517442 }} </ref> and [[primary CNS lymphoma]]<ref name="pmid15747120">{{cite journal| author=Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H et al.| title=Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. | journal=Ann Hematol | year= 2005 | volume= 84 | issue= 7 | pages= 447-55 | pmid=15747120 | doi=10.1007/s00277-005-1005-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15747120 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | |||
[[Category:Chemotherapy regimens]] | |||
Latest revision as of 14:55, 31 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
ProMACE-MOPP regimen refers to a regimen consisting of prolix (prednisone), methotrexate, adriamycin (doxorubicin), cyclophosphamide, etoposide, mustargen (mechlorethamine), oncovin (vincristine), procarbazine, prednisone used to treat diffuse large B-cell lymphoma[1] and primary CNS lymphoma.[2]
Regimen
ProPrednisone
MMethotrexate
AAdriamycin (Doxorubicin)
CCyclophosphamide
EEtoposide
MMustargen (Mechlorethamine)
OOncovin (Vincristine)
PProcarbazine
PPrednisone
Indications
References
- ↑ 1.0 1.1 Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A; et al. (1994). "MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group". J Clin Oncol. 12 (7): 1366–74. PMID 7517442.
- ↑ 2.0 2.1 Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H; et al. (2005). "Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma". Ann Hematol. 84 (7): 447–55. doi:10.1007/s00277-005-1005-9. PMID 15747120.